ImmunityBio
IBRX
64 hedge funds and large institutions have $32.8M invested in ImmunityBio in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 8 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 62 → 64 (+2)
0.4% less ownership
Funds ownership: 14.14% → 13.74% (-0.4%)
25% less capital invested
Capital invested by funds: $43.5M → $32.8M (-$10.7M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$808K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$473K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$370K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$349K |
| 5 |
Bank of New York Mellon
New York
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.6M |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.45M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$896K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$414K |
| 5 |
VF
Virtu Financial
New York
|
-$180K |
IBRX Hedge Fund Activity: Q2 2018 in Review
64 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2018, worth a combined $32.8M — down 25% from $43.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IBRX positions and 8 closed out — a net gain of 2 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $808K. The largest seller was Vanguard Group, cutting an estimated $1.6M.
- 64 institutional investors held ImmunityBio (IBRX) as of Q2 2018, up from 62 in Q1 2018.
- Funds reported $32.8M of ImmunityBio stock for Q2 2018, down 25% quarter-over-quarter.
- 10 funds opened new ImmunityBio positions in Q2 2018 and 8 closed out, a net change of +2 holders.
- The largest ImmunityBio buyer in Q2 2018 was Renaissance Technologies, an estimated $808K added.
- The largest ImmunityBio seller in Q2 2018 was Vanguard Group, an estimated $1.6M sold.
Based on aggregated 13F filings for Q2 2018.